Marconi P, Bistoni F, Cassone A, Frati L, Baccarini M, Garaci E, Bonmassar E
Cancer Immunol Immunother. 1982;13(2):128-33. doi: 10.1007/BF00205313.
The influence of the route of administration and treatment schedule of a yeast immunoadjuvant, Candida albicans (CA) on the degree of success achieved with an immunochemotherapy regimen in a virus-induced murine lymphoma has been evaluated. To this end, histocompatible CD2F1 mice received IP or IV inoculations of LSTRA lymphoma cells and were subjected to various treatments with inactivated CA and bis,1,chloroethyl nitrosourea (BCNU). The results showed that CA may significantly increase the antitumor efficiency of BCNU when (a) the tumor is inoculated IP and not IV; (b) CA is administered before (on day -14) and after (on days +1 and/or day +8) LSTRA challenge; (c) CA is given IP as a post-tumor treatment. To ascertain whether the immunoadjuvant effect was anatomically restricted to the peritoneal cavity (PC), spreading of IP injected lymphoma was studied by means of LSTRA cells labeled with 3-5'iodo-deoxyuridine 125I (125IUdR) and tumor bioassay in spleen, lung, kidney, liver, and PC of recipient mice. The results showed that IP tumor challenge led to early (1 h) generalized neoplasia in both untreated and CA-pretreated hosts. Therefore, the combined antitumor effects of chemotherapy and CA are not restricted to the PC but rather the result of systemic immunity. In conclusion, in our system the PC seems to be a preferential site for eliciting generalized antilymphoma host responses markedly amplified by selected schedules of immunoadjuvant administration.
已评估酵母免疫佐剂白色念珠菌（CA）的给药途径和治疗方案对病毒诱导的小鼠淋巴瘤免疫化疗方案成功程度的影响。为此，组织相容性CD2F1小鼠接受腹腔注射（IP）或静脉注射（IV）LSTRA淋巴瘤细胞，并接受用灭活CA和双（1-氯乙基）亚硝脲（BCNU）进行的各种治疗。结果表明，当（a）肿瘤通过腹腔注射而非静脉注射接种；（b）CA在LSTRA攻击前（第-14天）和后（第+1天和/或第+8天）给药；（c）CA作为肿瘤后治疗进行腹腔注射时，CA可显著提高BCNU的抗肿瘤效率。为确定免疫佐剂作用在解剖学上是否仅限于腹腔（PC），通过用125I-5'-碘脱氧尿苷（125IUdR）标记的LSTRA细胞和受体小鼠脾脏、肺、肾、肝和PC中的肿瘤生物测定法研究了腹腔注射淋巴瘤的扩散情况。结果表明，腹腔注射肿瘤攻击在未治疗和CA预处理的宿主中均导致早期（1小时）全身性肿瘤形成。因此，化疗和CA的联合抗肿瘤作用不限于腹腔，而是全身免疫的结果。总之，在我们的系统中，腹腔似乎是引发全身性抗淋巴瘤宿主反应的优先部位，通过选定的免疫佐剂给药方案可显著增强这种反应。
